Colin McDowell
Senior Manager, Business Development Biodesix
Seminars
Tuesday 27th October 2026
Measuring Target Degradation in Peripheral Blood Mononuclear Cells: Development of a KIF22 Pharmacodynamic Biomarker for the Clinic
11:30 am
- Discovery proteomics identified KIF22 peptides that enable direct measurement of target abundance in PBMCs and demonstrated selective degradation in degrader-treated cell models
- Pre-analytical studies evaluated blood collection, PBMC isolation, and sample handling variables influencing KIF22 detection and assay performance
- A targeted PRM assay achieved a 50 amol lower limit of quantification and reproducible performance across donor matrices, supporting pharmacodynamic assessment in clinical development
